Propanc Biopharma Inc (NASDAQ: PPCB) is a clinical-stage biotechnology company developing enzyme-based cancer therapies, with no approved products and no commercial revenue as of its 10-K filed September 29, 2025. The company generates no product revenue and funds operations entirely through debt and equity financing, including convertible notes and equity line agreements with parties such as Coventry Enterprises, Dutchess Capital Growth Fund, and 1800 Diagonal Lending. Its lead product candidate, PRP, is an investigational proenzyme formulation targeting advanced solid tumors, with a planned First-in-Human Phase Ib study followed by two Phase II trials evaluating safety, pharmacokinetics, and anti-tumor efficacy. R&D activities are fully outsourced to contract research and manufacturing organizations, including Amatsigroup NV (formerly Q-Biologicals NV). As of September 25, 2025, PPCB had 103 record holders of its common stock and had not paid any cash dividends. The balance sheet carries convertible notes, loans payable to related parties, and embedded derivative liabilities, reflecting a pre-revenue capital structure reliant on successive financing transactions.

Revenue model

No product revenue. Operations funded through issuance of convertible notes, equity lines, and securities purchase agreements with third-party lenders and investors. No disclosed royalty, licensing, or commercial revenue stream as of the 10-K filed September 29, 2025.

Products and services

PRP: investigational proenzyme-based oncology therapy targeting advanced solid tumors, in planned Phase Ib and Phase II clinical development as of the 10-K filed September 29, 2025.

Customers and end markets

No commercial customers. End market is oncology, specifically patients with advanced solid tumors. Clinical development stage only as of filing date September 29, 2025.

Value-chain role

Drug development sponsor. Fully outsources R&D, manufacturing, and quality assurance to contract organizations including Amatsigroup NV. Acts as clinical sponsor and IP holder without internal manufacturing or commercial sales capability.

Geographic exposure

Incorporated and headquartered in the United States, listed on Nasdaq. Plans to conduct clinical trials across multiple foreign jurisdictions in addition to the United States, subject to local regulatory approvals, per the 10-K filed September 29, 2025.

Source: SEC 10-K, filed 2025-09-29

Industry: Pharmaceutical Preparations Peers: Kazia Therapeutics Ltd